Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock Position Raised by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 141.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 190,457 shares of the biopharmaceutical company's stock after acquiring an additional 111,485 shares during the period. JPMorgan Chase & Co. owned approximately 0.29% of Regulus Therapeutics worth $301,000 as of its most recent SEC filing.

Separately, Barclays PLC raised its stake in shares of Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock valued at $132,000 after purchasing an additional 62,549 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

RGLS has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Regulus Therapeutics in a report on Friday, March 14th. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $9.00 target price on shares of Regulus Therapeutics in a research report on Thursday, May 1st. Leerink Partnrs downgraded Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 30th. Canaccord Genuity Group restated a "hold" rating and set a $11.00 price objective (down from $28.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Finally, Leerink Partners reiterated a "market perform" rating and set a $7.00 target price on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $8.50.

Regulus Therapeutics Stock Performance

NASDAQ RGLS remained flat at $7.85 during trading hours on Thursday. The company's stock had a trading volume of 121,634 shares, compared to its average volume of 1,501,296. The company has a market cap of $520.01 million, a price-to-earnings ratio of -7.34 and a beta of 0.49. Regulus Therapeutics Inc. has a 1 year low of $0.83 and a 1 year high of $8.20. The business has a fifty day moving average of $2.50 and a two-hundred day moving average of $1.79.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.20). During the same quarter last year, the business earned ($0.40) EPS. On average, equities research analysts expect that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.